Abstract: Computational assessment of the binding affinity of enzyme inhibitors prior to synthesis is an important component of computer-aided drug design (CADD) paradigms. The free energy perturbation (FEP) methodology is the most accurate means of estimating relative binding affinities between two inhibitors. However, due to its complexity and computation-intensive nature, practical applications are restricted to analysis of structurally-related inhibitors. Accordingly, there is a need for methods that enable rapid assessment of a large number of structurally-unrelated molecules in a suitably accurate manner. In this review, the FEP method is compared with molecular mechanics (MM) methods to assess the advantages of each in the estimation of relative binding affinities of inhibitors to an enzyme. Qualitative predictions of relative binding free energies of fructose 1, 6-bisphosphatase inhibitors using MM methods are discussed and compared with the corresponding FEP results. The results indicate that the MM based methods and the FEP method are useful in the qualitative and quantitative assessment of relative binding affinities of enzyme inhibitors, respectively, prior to synthesis.
INTRODUCTION
Computer-assisted drug design (CADD) approaches have contributed to the successful discovery of novel numerous enzyme inhibitors, including inhibitors of thymidylate synthase [1] , HIV-1 Protease [2] and purine nucleoside phosphorylase inhibitors [3] . In each case, CADD was used to predict the binding affinity of an inhibitor designed from a lead compound prior to synthesis. A free energy simulation technique known as the thermodynamic cycle perturbation (TCP) approach [4] used in conjunction with molecular dynamics calculations offers a theoretically precise method of determining the binding free energy differences of related inhibitors. Despite its high accuracy, free energy calculations [5, 6] have been used primarily to rationalize known binding affinities, with few reports demonstrating its potential for drug discovery [7, 8] .
Earlier, Reddy et al. reported results using the free energy perturbation (FEP) calculations in an iterative structurebased design program to accurately predict relative binding affinities of inhibitors to an HIV-1 protease inhibitors [8] . Recently, Erion and Reddy [9, 10] used free energy perturbation methodology to calculate relative binding free energies of a series of fructose 1, 6-bisphosphatase (FBPase) inhibitors and rank order the contributions of individual ligand heteroatoms to the overall ligand binding affinity.
The FBPase catalyzes the hydrolysis of fructose 1, 6-bisphosphate to fructose 6-phosphate (F6P) and inorganic phosphate and is a key regulatory enzyme in the gluconeogenesis pathway [11] . The FBPase is an important target for *Address correspondence to this author at the Metabasis Therapeutics, Inc, 9390 Towne Centre Drive, San Diego, CA 92121, USA; E-mail: reddy@mbasis.com gluconeogenesis pathway [11] . The FBPase is an important target for type II diabetes drugs based on its central role within the gluconeogenesis pathway and the association of this pathway with the excessive production of glucose by the livers of patients with diabetes mellitus [12, 13] . Discovery of potent and selective inhibitors of FBPase represents a significant challenge for medicinal chemists due to the hydrophilic nature of both the substrate binding site and the allosteric regulatory site. The latter site binds adenosine monophosphate (AMP), which induces a protein conformational change that results in decreased enzymatic activity.
This review focuses on lead inhibitor optimization strategies using the free energy perturbation approach and molecular mechanics methods and evaluates the merits of each method for predicting relative binding affinities of inhibitors to FBPase.
COMPUTER AIDED DRUG DESIGN (CADD) STRATEGIES

Computer Aided Drug Design Scheme
High-resolution X-ray structures of pig and human FBPase [14, 15] were used to study the interactions of potential ligands with the allosteric binding site [9, 10] , and design new analogs. Methods used to design inhibitors ranged from graphical visualization of the ligand in the binding site cavity to calculation of relative binding affinities using molecular dynamics simulations in conjunction with the FEP approach [4] . Fig. (1) shows a typical flowchart employed by drug discovery groups using different CADD approaches. This review article is focused on the discovery of potential drug candidates using the CADD methods in conjunction of X-ray crystallography. The process begins by generating a working computational model from crystallographic data. This step usually entails developing molecular mechanics force field parameters for non-standard residues, assigning the protonation states of histidines, and orientating carbonyl and amide groups of asparagine and glutamine amino acid residues based upon neighboring hydrogen bond donor/acceptor groups. Characterization of the active site is then aided by a variety of visualization tools. For example, hydrophobic and hydrophilic regions of the active site are readily identified by calculating the electrostatic potential at different surface grid points. The information gained by graphical analysis of the active-site aids new lead design and optimization of the lead through analog design.
Lead Generation
The following three methods are often used for discovery of lead compounds.
De Novo Drug Design Methods
De novo drug design requires a 3-dimensional structure of the target protein. A few successes are reported but overall de novo design represents a goal and not a reality. De novo molecular design methods have been used to design new structures by sequentially adding molecular fragments to a growing structure, by adding functionality to an appropriately sized molecular scaffold, or by adding fragments building toward the center of a molecule starting from distant sites thought to interact with the target [16] [17] [18] . These approaches can be used for generating diverse molecular structures.
Database Search Methods
In some cases, new lead compounds have been identified by screening structures found in databases of known [19] [20] [21] commercial as well as proprietary chemical databases for particular structural features using three dimensional structure of a target protein with known active site. In addition, database search methods have been developed that search databases for compounds that have particular molecular functionality separated by a specified number of bonds or distance ranges. More chemically intuitive database search methods search for chemicals with particular steric and electrostatic fields [22] .
Combinatorial Methods
This method doesn't require target protein structure which is the main requirement for other two methods. Combinatorial chemistry helps to create a large library of structures with diversity. A growing number of drug leads are generated by combinatorial methods in combination with high-throughput screening [23] [24] [25] .
Optimization of Lead Compounds
Optimization of lead compounds is often a step-wise process using computational methods in combination with SAR information to determine areas on the molecule to expand, contract, or modify. Accordingly, the challenge is, to prioritize a large diverse set of molecules to a small set of compounds that have the highest likelihood to bind. Methods that rapidly and accurately predict absolute binding affinities represent the long-term goals. Currently, the methods range from being able to provide qualitative rank ordering of a large number of molecules in a relatively short period of time [26] or to free energy methods that generate quantitatively accurate predictions of relative binding affinities for structurally related molecules by using significant computing power [7] [8] [9] [10] . Fig. (2) shows typical flowchart used for optimization of lead compounds using CADD methods. A large percentage of the proposed analogs can usually be eliminated by evaluating their expected binding affinities based on graphical analysis, desolvation costs, conformational analysis and empirical scoring/docking [27, 28] . The remaining analogs are prioritized using one or all of the following methods, depending on the availability of computational power, time and resources: i) Free Energy Perturbation (FEP) calculations, which provide accurate predictions, but are computationally very expensive [7] [8] [9] [10] , ii) molecular mechanics calculations, which provide rapid qualitative predictions [26, 29] , and iii) regression methods [26, 30] that incorporate interaction variables and ligand properties, which provide semi-quantitative predictions and are much faster than FEP calculations. The top scoring compounds are synthesized and tested for activity. The process is repeated in an iterative fashion until potential drug candidates are identified with the desired biological activity.
FREE ENERGY PERTURBATION (FEP) METHOD
Application of the FEP methodology [31] to the design of FBPase inhibitors began following the analysis of accuracy of the method using the FBPase crystal structure complexed with known ZMP inhibitor [14] .
Thermodynamic Cycle-Perturbation (TCP) Approach
The TCP approach [4, 31] was used to compute relative changes of binding free energy. The TCP method entails the construction of non-physical paths connecting the desired initial and terminal states. This approach enables the calculation of relative change in solvation free energy (∆∆G sol ) and binding free energy (∆∆G bind ) between two related compounds, by computationally simulating the 'mutation' of one to the other. The relative solvation free energy change for two substrates is computed using the solvation cycle shown in Fig. (3) , represented in the following equation: The relative free energy of binding is the difference in two affinities, i.e. the affinity of the ligand for the protein (∆G com ) and the affinity of the ligand for water (∆G aq ) which are computed using the binding cycles shown in Fig. 3 . Equation 2 is used to calculate ∆∆G bind : -k β T ln (k2/k1) = ∆G com -∆G aq = ∆∆G bind (2) where the experimentally measured binding constants k1 and k2 refer to the reactions involving S1 and S2 inhibitors respectively, and their corresponding free energy differences are ∆G 1 and ∆G 2 , k β is the Boltzmann constant and T is the absolute temperature.
The free energy change for converting S1 into S2 is computed by perturbing the Hamiltonian of reactant (initial) state S1 into that of the product (final) state S2. This transformation is accomplished through a parameterization of terms comprising the interaction potentials of the system with a change of state variable that maps onto reactant and product states when that variable is 0 and 1 respectively. The total free energy change for the mutation from the initial to the final state is computed by summing 'incremental' free energy changes over several windows visited by the state variable changing from 0 to 1.
Computational Details
All molecular dynamics, mechanics and TCP calculations were carried out with the AMBER program using an all atom force field [32] and SPC/E model potential [33, 34] to describe water interactions. Electrostatic charges and parameters for the standard residues were taken from the AMBER database. For non-standard solute atoms, partial charges were obtained by using CHELPG [35] to fit the ab initio 6-31G* basis set level wave functions calculated with Gaussian94 [36] . All equilibrium bond lengths, bond angles, and dihedral angles for nonstandard residues were taken from ab initio optimized geometries. Missing force field parameters were estimated from similar chemical species within the AMBER database.
Solvation free energies were computed by solvating the solute with SPC/E water and using the AMBER box option. All solvent molecules >15.0 Å or <2.5 Å from the closest solute atom were removed. Aqueous phase molecular dynamics simulations were carried out in a rectangular box using periodic boundary conditions in all directions. Equations of motion for all the atoms were solved using the Verlet algorithm [37] with a 2 fs time step. Shake [38] was used to constrain all bond lengths. Constant temperature (N, P & T ensemble) was maintained by velocity scaling of all atoms in the system. Protein complex simulations were carried out using a computer model that was derived from the FBPase-ZMP Xray structure. The EDIT module of AMBER was used to add crystallographic waters and hydrogens to protein residues. The total charge on the FBPase tetramer complex was +4 e. No counter ions or changes in the customary charge of protein residues were used. While such an electrostatic model is far from ideal, alternative strategies are associated with numerous other drawbacks. The entire system was immersed in a 25.0 Å radius sphere of solvent centered around the mutating group and subjected to a half-harmonic restraint near the boundary to prevent evaporation. During the simulation, all atoms of the protein were fixed beyond 25.0 Å. All non-bonded interactions involving the inhibitors and the charged residues of the protein were computed with infinite cutoff. A 15.0 Å non-bonded residue based cutoff was used for other residues of the system. The algorithm for the complex simulation was identical to the solvent simulation, except for the absence of periodic boundary conditions in the former.
Relative solvation (∆∆G sol ) and relative binding (∆∆G bind ) free energies between AMP and its analogs complexed to FBPase were calculated using the thermodynamic cycle perturbation approach in conjunction with molecular dynamics (time step = 2 fs) simulations. In all free energy simulations, the system was initially equilibrated for 20 ps followed by 2.5 ps of equilibration and 5 ps of data collection for each window. A total of 51 windows were used for each complete mutation. Calculated results for each mutation represent the average of four calculations, i.e., forward and reverse mutations starting from AMP (L1) and its analog AMP (L2). Error bars are estimated for each window by dividing the window statistics into four groups and computing the standard deviation [10] . The root-mean-square of these window errors is reported as a measure of the statistical uncertainty in the results for each complete mutation.
STRUCTURAL ANALYSIS
AMP Model
FBPase is a tetrameric protein with four identical polypeptide chains (C1 to C4). C1 and C2 comprise the crystallographic n-symmetric unit. The X-ray structure of the ZMP: human liver FBPase complex was first solved at 2.3 Å resolution by Lipscomb and co-workers [14] . Analysis of the X-ray structure of the FBPase: ZMP complex shows that slight differences exist between each subunit with regard to the atomic positions for several binding site residues (e.g. Arg140 and Lys112 side-chains) as well as the number and position of water molecules. Consequently, we calculated the interaction energy of ZMP in each subunit. The calculated interaction energies after energy minimization indicated that the C4 subunit has the lowest energy (C4<C1<C3<C2). Accordingly, the ZMP binding site of the C4 subunit was used for all molecular modeling calculations.
Model Validation
A model of adenosine monophosphate (AMP) bound to the AMP binding site was built by first overlaying AMP on ZMP in the subunit C4 and was shown in Fig. (4a) with all the important active site protein residues.
The model was energy minimized using 500 steps of steepest descent followed by 2000 steps of conjugate gradient. The complex was then equilibrated with 20 ps MD simulation. The average 'dynamical' structure of the complex was computed from the MD simulation. For time steps of 1 fs and 2 fs, the root mean square deviations (Table 1 ) from the crystal structure were 1.10 Å and 1.17 Å for backbone atoms and 1.55 Å and 1.61 Å for side-chain atoms, respectively. As expected, the largest deviations were observed on the surface (with RMS deviations of 1.28 Å and 1.70 Å for backbone and side chain atoms, respectively) when compared to the rest of the protein. This is primarily due to the flexibility of the protein in the surface region. Nevertheless, the dynamical structure is a good model for calculating relative free energy changes between two similar inhibitors. Since both time steps gave similar structures and are in good agreement with the X-ray structure, we used the larger time step, i.e. 2 fs, for all the free energy calculations reported, to minimize the computer time. The electrostatic potential surface of the allosteric binding site of the FBPase: AMP complex is shown in Fig. (4b) . The surface color red and green indicate hydrophilic and hydrophobic regions of the AMP binding site, respectively. 
FREE ENERGY PERTURBATION CALCULATIONS
FEP Methodology Validation
The X-ray structure of FBPase complexed with AMP (shown in Fig. (4b) ) inhibitor was used as a starting model (Fig. (5a) ) was performed to test the validity of our protocol. Since this mutation involves significant changes in ligand structure, the 'thread' method [10] was used to accomplish the transformation. For this mutation, the bases of ZMP and AMP are 'threaded' together at C 1 ' (Fig. (5b) ). The calculated difference in binding free energy of 1.70±0.9 kcal/mol is in good agreement with the experimentally measured free energy difference of 1.4 kcal/mol. These results indicate that ZMP binds to FBPase with lower affinity relative to AMP.
The lower affinity appears to be due to the higher desolvation free energy of ZMP (1.5 kcal/mol), which results from the increased number of hydrogen bonds formed to solvent water, and the increased conformational freedom (higher entropy) of ZMP relative to AMP.
Binding Affinity Predictions using FEP Method
Based on the graphical analysis of AMP binding site (Fig. (4a-b) ) the following four types of new analogs were proposed: i) substitutions at C5' position, ii) substitutions on ribosyl ring hetero atoms, iii) substitutions on pyrimidine ring, and iv) substitutions on imidazole ring. The final list of FBPase inhibitors considered for FEP predictions is shown in Fig. (6a-c) .
Substitutions at C5' Position
Hydrogen bond analysis of FBPase:AMP complex active site (Fig. (4a-b) ) indicates that phosphate hydrogen bonds, 6-amino group hydrogen bonds, and N7 hydrogen bond, with AMP binding site protein residues, may be very important to the binding affinity of AMP to FBPase enzyme. However, ample evidence has indicated that phosphate inhibitors make poor drug candidates [39] . As a result, we focused our efforts to discover phosphate mimics. Based on the graphical, conformational and desolvation analysis the compounds 3, 4, 5 and 6 (Fig. (6a) Fig. (6a) . Substituted C5' and ribosyl ring hetero atoms of AMP analogs.
We performed five mutations, 2 → 3, 2 → 4, 2 → 5, 2 → 6 and 4 → 5, and calculated relative solvation and binding free energies. For the mutations with compounds 5 and 6 as in the former mutation a thread method was used because of the large change involved. For the other mutations, 2 → 3 and 2 → 4, a single topology method was used. In this commonly used method, appropriate reactant atoms will change to appropriate product atoms including changes in the geometry, partial charges and van der Waal's para- O O meters. In Table 2 , we reported calculated relative differences in the solvation and binding free energies for mutations. For the mutations, 2 → 4 and 2 → 5, the qualitative trend of calculated results clearly indicate lower binding affinity of compounds 4 and 5 to FBPase enzyme as compared to AMP. However, the calculated free energy results were not meaningful for quantitative estimation of binding affinities between these compounds, because of a large change in the charge from -2 e (phosphate) to -1 e (carboxylate or sulfate) during the mutation.
The free energy results ( Table 2 ) between 4 and 5 indicate that compound 4 costs about -4.5 kcal/mol desolvation penalty, but gained significant energy in the complex due to extra hydrogen bonds between sulfate oxygens and protein residues. Therefore, compound 4 is a better inhibitor to FBPase enzyme than the compound 5. The free energy results between compounds 2 and 3 show ( Table 2 ) that compound 3 costs less to desolvate by 1.0 kcal/mol. However, it losts significantly in the complex due to the loss of a hydrogen bond with Tyr 113 hydroxyl group, and also some changes in the interaction energies of the phosphonate (3) group with protein residues as compared to compound 2 (AMP). As a result, compound 3 is a very weak inhibitor (3.9 Kcal/mol) to FBPase enzyme compared to AMP. Based on the calculated free energies, compound 6 is associated with a 2.9 kcal/mol desolvation penalty but gains about 1.3 kcal/mole in the complex as compared to AMP. Thus, the compound 6 is a weaker inhibitor to FBPase enzyme than the compound 2 (AMP). In conclusion, all four new analogs evaluated as potential phosphate mimics, using the FEP method, indicated weaker binding affinity relative to a lead compound AMP. Later some of these compounds were synthesized and shown to have relative binding affinities ( Table 2 ) that agreed with the calculated results.
Substitutions on Ribosyl Ring Hetero Atoms
Since phosphate mimics proved to have lower potency relative to the phosphate (2), we turned to evalvating analogs with modifications of heteroatoms within the ribosyl ring (compounds 7 -9, Fig. (6a) ). The relative solvation and Table 2 ) but none of these analogs were a better inhibitor of FBPase than AMP (2).
Substitutions on Pyrimidine Ring
Since compounds 3 to 9 were not as potent as 2 ( Table  2) , our attention focused on making changes to the purine base while keeping the phosphate group unchanged. The Xray structure of the FBPase-AMP complex revealed unfilled space near N1, C2 and N3. Since the residues in the vicinity were hydrophobic and neither N1 nor N3 participated in a hydrogen bond with the protein, compounds 10 to 13 (Fig.  (6b) ) were designed with the anticipation that they would gain hydrophobic interactions with Met 188. Compounds 14 to 18 (Fig. (6b) ) were designed with the expectation that they would reduce desolvation energy cost. Fig. (6b) . Substituted AMP analogs on pyrimidine ring.
Since the each mutation between 2 and its analogs (10 -18) involve relatively minor changes in the inhibitor structures, a single topology for the reactant and product molecules was used as described in the earlier mutation. The calculated free energies were given in Table 2 and the results indicated that all the molecules, except compound 11, were better inhibitors to FBPase enzyme than the lead compound 2. These results were supported by results generated with compounds that were synthesized and analyzed for inhibitor potency ( Table 2 ).
An X-ray structure of FBPase complexed with compound 2 showed (Fig. (4b) ) two strong hydrogen bonds between the 6-amino group and the hydroxyl of Tyr 31 and with backbone carbonyl oxygen of Val. In addition, the complex exhibited a strong hydrogen bond between N7 and hydroxyl group of Thr31. In order to understand the importance of 6-amino hydrogen bonds to the binding affinity of FBPase enzyme, the compounds 19 to 21 (Fig. (6b) ) were designed and evaluated using FEP methods. The relative solvation and binding free energies were calculated ( Table 2) between pairs of the compounds: 2 → 19, and 2 → 20, 2 → 21. The calculated relative solvation and binding free energies between these pairs of molecules, 2 → 19, 2 → 20, and 2 → 21 are -4.50 Kcal/mol, -4.9 Kcal/mole, -4.0 Kcal/mol, and 1.5 Kcal/mol, 1.8 Kcal/mole, 2.3 Kcal/mol, respectively. These results suggest that binding preference of 2 (AMP) to FBPase is due to the strong hydrogen bonds of the 6-amino group with Val 17 and Thr 31. These two hydrogen bonds dominate an opposing contribution arising from the large desolvation penalty of AMP relative to des-amino analogs (compounds 19-21) . The larger desolvation penalty of AMP is due to the two hydrogen bonds between water and hydrogens of 6-amino group as compared to des-amino analogs.
Substitutions on Imidazole Ring
Finally, compounds 22 and 23 (Fig. (6c) ) were evaluated to understand the contribution of the hydrogen bond between N7 and the hydroxyl group of Thr31. The mutations between compounds, 2 → 22 and 2 → 23, were completed using the FEP method and results are given in Table 2 . The desolvation gain for 22 is about 0.8 kcal/mol as compared to AMP, but loses one strong hydrogen bond and therefore, the compound 22 is a very weak (2.8 Kcal/mol) inhibitor to FBPase enzyme as compared to AMP. The major difference between compounds 2 and 23 is N7 hydrogen bond donor (2) versus acceptor (23) number of hydrogen bonds with protein residues with solvent water. However, the calculated relative free energy result indicated a small loss in the free energy in the complex for the compound 2 that was more than compensated by its lower desolvation costs as compared to 23. These changes in the free energy, both in the solvent and in the complex, could be due to the loss of intramolecular hydrogen bond between N7 and 6-amino group and the change in the geometry of 6-amino group. The net result is that compound 2 (AMP) is a slightly (0.6 Kcal/mol) better inhibitor to FBPase enzyme than compound 23. These results indicate that the hydroxyl group of Thr31 forms a hydrogen bond with N7 of the inhibitor, either by donating a proton or accepting a loan pair. Accordingly, new analogs that use N7 either as a donor or an acceptor were determined as potential synthetic candidates.
In summary, the relative solvation free energies (∆∆G sol ) and binding free energies (∆∆G bind ) were calculated for the pairs of inhibitors shown in Fig. (6a-c) . Using the X-ray structure of FBPase complexed with ZMP, binding affinities were predicted [9, 10] prior to synthesis. Later, some of the compounds were synthesized and K i 's were measured. The predicted relative binding free energies and experimental results are shown in Table 2 . The comparison of predicted relative binding affinities with available experimental results showed very good agreement. This was the first study, that involved a large set of molecules whose relative binding affinities were predicted using the FEP method prior to synthesis. Confirmation of the predictions with experimental measurements suggested that the method was useful for the design of novel inhibitors for the FBPase.
MINIMIZATION METHODS
While the TCP method is useful in the prediction of relative binding affinities of structurally similar inhibitors, real-life drug design problems involve the calculation of binding affinities for inhibitors with a greater degree of structural dissimilarity. Hence, faster methods that can accommodate structural diversity are needed. In some cases predictions of inhibitor binding has been based soley on a visual analysis of structures without any force field calculations. These methods relied on graphical analysis of features such as steric and electronic complementary of the docked inhibitor to the target protein, the extent of buried hydrophobic surface and the number of rotatable bonds in the inhibitor. Quantitative descriptors based on molecular shape [27] and grid-based energetics [40] have proven useful in drug design. More advanced methods have been used to generate empirical scoring functions [41] derived from crystal structure data and experimental binding affinities. Although molecular mechanics methods appear to be more useful in this regard, these methods met with only limited success initially [42] , due to the large approximations involved in the analysis (e.g., solvent model used, lack of entropic terms etc.). A few successful studies evaluate interaction energies and ligand strain in ananalysis of various binding conformations of new analogs. The purine nucleoside phosphorylase (PNP) inhibitors [3, 43] were designed successfully using these methods. Minimization methods were also used for predicting relative binding affinities of HIV1 protease inhibitors [29] using energies obtained both in solvent as well as complex phases of each inhibitor.
Recently we considered a study in which relative binding affinities of FBPase inhibitors were estimated using relative energies obtained from minimization methods [44] . In this example, the binding modes of the putative/proposed inhibitors were obtained by carefully aligning them with the known crystal structures of inhibitors in the active site of the FBPase. These inhibitors which are shown in Fig. (6a-c) were then evaluated by performing minimization calculations both in solvent and in complex using the AMBER [32] force field. The following are the technical details used for estimating relative binding affinities using energy components obtained from minimizations of each inhibitor both in solvent as well as in complex phases.
Computational Details
FBPase inhibitors considered for this study are the same as inhibitors used in the FEP calculations discussed earlier (Fig. (6a-c) ) and also, complex and solvent setups and system conditions are the same as in FEP calculations. Molecular mechanics calculations (energy minimizations) on all the structures were performed using the BORN module of the AMBER program. A four-stage protocol was set up for energy minimizations of the protein-inhibitor complex. Minimization at each stage was performed using 100 steps of steepest descent and 1500 steps of conjugate gradient algorithms for minimization. In the first stage, only the water molecules were minimized, keeping the inhibitor and the protein (in the complex calculation) fixed. The purpose of this step is to relieve any bad contacts involving water molecules in the initially solvated system. In the second stage, only hydrogens in the system were allowed to relax. This step relaxes the hydrogen atoms prior to relaxing heavy atoms. It was performed because the hydrogen locations are not specified by the X-ray structure and because adjustments in hydrogen atom locations are necessary to improve hydrogen bond geometries. The third stage was performed for all the modified ligand-protein complexes (i.e., when the ligand is modified from the original ligand in an X-ray structure complex). In this third stage, all atoms of the protein were fixed and atoms common to the ligand in the crystal structure complex and the modified ligand were also fixed, while allowing the modified group in the ligand and the solvent to move during optimization. This stage allows for the relaxation of the modified group with respect to the protein and establishes the preferred interactions (e.g., hydrogen bonds). In the fourth and final stage, all atoms of all residues within 25 Å of any atom from the center of the modified group (waters, protein atoms and the ligand) were allowed to relax.
A four-stage protocol was also established for energy minimization of the solvated inhibitor. These minimizations were carried out using periodic boundary conditions in all directions and in each stage involved 100 steps of steepest descent and 1500 steps of conjugate gradient optimization. In the first stage of minimization, only the waters were minimized keeping the inhibitor (i. e., the solute) fixed. In the second stage, only hydrogens in the system were allowed to relax. In the third stage, atoms common to the ligand in the crystal structure complex and the modified ligand were also fixed, while allowing the solvent and the modified group in the ligand to move during optimization. In the fourth stage of the solvent calculation, all water molecules and the solute (ligand) were allowed to relax.
Results and Discussion
The minimized structures for all the 23 inhibitors in the complexed and solvated states were used for calculating the following energy variables:
where, ∆E bind (intra) and ∆E bind (inter) are relative intra and intermolecular binding interaction energies of a ligand, respectively, and where E com (intra), E com (inter), E sol (intra), and E sol (inter) are intra and intermolecular interaction energies of a ligand in the complexed and solvated states, respectively. Relative differences in intra, intermolecular and total binding interaction energies for a pair of ligands L1 and L2 are given by, ∆∆E bind (intra:L1 → L2) = ∆E bind (intra:L2) -∆E bind (intra:L1)
∆∆E bind (inter:L1 → L2) = ∆E bind (inter:L2) -∆E bind (inter:L1) (6) ∆∆E bind (tot:L1 → L2) = ∆∆E bind (intra:L1 → L2) + ∆∆E bind (inter:L1 → L2)
where, ∆∆E bind (tot:L1 → L2) is the total relative difference in the binding energies of L1 and L2.
It is expected that such scores computed from energy minimizations are associated with uncertainties and will not match the quality of results from obtained using free energy methods. Hence, an agreement in the overall trends between the free energy results or experimental measurements and the energy minimization results were expected. In the Table 3 , the relative differences in the binding free energies measured experimentally (∆∆G bind (expt)) are compared with the relative binding energies calculated using minimization methods and for all the cases the minimizations results provided qualitative agreement with experimental results. However, as shown in Table 3 these energy differences do not agree quantitatively with experimental binding free energies. Therefore, this approach could be very useful for screening a larger set of compounds only qualitatively before computationally expensive free energy calculations are performed.
CONCLUSIONS
A comparison of the calculated and experimental relative binding affinities for structurally similar inhibitors to FBPase indicate that the FEP method is more accurate, but it suffers from practical limitations due to its relative complexity and computation-intensive nature. Accordingly, there is a need for methods that enable rapid assessment of large number of structurally unrelated molecules in a reasonably accurate manner. Energy components calculated by performing molecular mechanics calculations both in explicit solvent and complex states are sufficient to estimate the relative binding free energy differences between two inhibitors qualitatively. These qualitative methods will continue to improve and become more accurate as; 1) force field parameters become more refined, 2) other variables important for binding such as entropy are included, 3) methods for estimating relative binding entropy changes improve, 4) docking and scoring procedures improve, and 5) average molecular dynamics simulations are used to obtain energy variables. These results clearly indicate that before synthesis and biochemical testing of new analogs, one can use molecular mechanics based methods for qualitative assessment of relative binding affinities of enzyme inhibitors and then use FEP simulations for more quantitative analysis of the most promising candidates.
